Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX15 | P16050 | 1/20 | 0.66 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.63 |
| ▸ | HPGD | P15428 | 3/20 | 0.63 |
| ▸ | RAB9A | P51151 | 3/20 | 0.63 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.63 |
| ▸ | NPC1 | O15118 | 2/20 | 0.63 |
| ▸ | LMNA | P02545 | 2/20 | 0.63 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.63 |
| ▸ | MEN1 | O00255 | 1/20 | 0.63 |
| ▸ | GLA | P06280 | 1/20 | 0.63 |
| ▸ | GAA | P10253 | 1/20 | 0.63 |
| ▸ | MAPT | P10636 | 1/20 | 0.63 |
| ▸ | ATM | Q13315 | 1/20 | 0.63 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.61 |
| ▸ | HTT | P42858 | 1/20 | 0.57 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.57 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.57 |
| ▸ | MMP13 | P45452 | 8/20 | 0.56 |
| ▸ | MMP2 | P08253 | 6/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL832201 | 0.91 | ALOX15 (0.69) | ALOX15KDM4EALDH1A1HPGDRAB9A | |
| SCHEMBL7681890 | 0.88 | ALDH1A1 (0.70) | ALOX15KDM4EALDH1A1HPGDRAB9A | |
| SCHEMBL1397976 | 0.87 | ALOX15 (0.64) | ALOX15KDM4EALDH1A1HPGDRAB9A | |
| SCHEMBL3276358 | 0.86 | ALOX15 (0.63) | ALOX15KDM4EALDH1A1HPGDRAB9A | |
| SCHEMBL22760538 | 0.86 | ALOX15 (0.63) | ALOX15KDM4EALDH1A1HPGDRAB9A | |
| SCHEMBL3542541 | 0.86 | ALOX15 (0.63) | ALOX15KDM4EALDH1A1HPGDRAB9A | |
| SCHEMBL29641398 | 0.86 | ALOX15 (0.63) | ALOX15KDM4EALDH1A1HPGDRAB9A | |
| SCHEMBL1397981 | 0.85 | ALOX15 (0.61) | ALOX15KDM4EALDH1A1HPGDRAB9A | |
| SCHEMBL18331899 | 0.84 | ALOX15 (0.64) | ALOX15KDM4EALDH1A1HPGDRAB9A | |
| SCHEMBL23049705 | 0.83 | ALOX15 (0.63) | ALOX15KDM4EALDH1A1HPGDRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2017156181-A1 | 3-PHOSPHOGLYCERATE DEHYDROGENASE INHIBITORS AND USES THEREOF | RAZE THERAPEUTICS, INC. (US) | 2017-09-14 | — | — | WO | disclosed |
| EP-1370561-B1 | TETRAHYDRO-PYRAZINO[1,2-A]INDOLES FOR THE TREATMENT OF CENTRAL NERVOUS DISORDERS | HOFFMANN LA ROCHE (CH) | 2009-02-11 | — | — | EP | disclosed |
| US-7253281-B2 | Anti-obesity 1,2,3,4,10,10a-hexahydropyrazino[1,2-a]indoles | HOFFMANN-LA ROCHE INC. (US) | 2007-08-07 | — | — | US | disclosed |
| US-20070106076-A1 | Anti-obesity 1,2,3,4,10,10a-hexahydropyrazino [1,2-a] indoles | BENTLEY JONATHAN M | 2007-05-10 | — | — | US | disclosed |
| US-7145009-B2 | Pirazino(aza)indole derivatives | VERNALIS RESEARCH LIMITED (GB) | 2006-12-05 | — | — | US | disclosed |
| US-20060160816-A1 | Pirazino(AZA) indole derivatives | VERNALIS RESEARCH LIMITED | 2006-07-20 | — | — | US | disclosed |
| US-20050239789-A1 | Anti-obesity 1,2,3,4,10,10a-hexahydropyrazino[1,2-a] indoles | BENTLEY JONATHAN M | 2005-10-27 | — | — | US | disclosed |
| EP-1325008-B1 | PIPERAZINE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2005-10-05 | — | — | EP | disclosed |
| US-6933387-B2 | Anti-obesity 1,2,3,4,10,10a-hexahydropyrazino[1,2-a]indoles | HOFFMANN-LA ROCHE INC. (US) | 2005-08-23 | — | — | US | disclosed |
| US-6844345-B2 | Piperazine derivatives | HOFFMAN-LA ROCHE INC. (US) | 2005-01-18 | — | — | US | disclosed |
| US-20040092525-A1 | Pirazino(aza)indole derivatives | VERNALIS RESEARCH LIMITED | 2004-05-13 | — | — | US | disclosed |
| US-20040039200-A1 | Pirazino(AZA)indole derivatives | VERNALIS RESEARCH LIMITED | 2004-02-26 | — | — | US | disclosed |
| EP-1370561-A2 | TETRAHYDRO-PYRAZINO[1,2-A]INDOLES FOR THE TREATMENT OF CENTRAL NERVOUS DISORDERS | F. HOFFMANN-LA ROCHE AG (CH) | 2003-12-17 | — | — | EP | disclosed |
| US-20030216401-A1 | Anti-obesity 1, 2, 3, 4, 10, 10a-hexahydropyrazino[1, 2-a] indoles | F. HOFFMANN-LA ROCHE AG (CH) | 2003-11-20 | — | — | US | disclosed |
| EP-1147110-B1 | PYRAZINO(AZA)INDOLE DERIVATIVES | VERNALIS RES LTD (GB) | 2003-05-07 | — | — | EP | disclosed |
| US-20020169163-A1 | Piperazine derivatives | HOFFMAN-LA ROCHE INC. | 2002-11-14 | — | — | US | disclosed |
| WO-2002072584-A2 | TETRAHYDRO-PYRAZINO (1,2-A) INDOLES FOR THE TREATMENT OF CENTRAL NERVOUS DISORDERS | F. HOFFMANN-LA ROCHE AG (CH) | 2002-09-19 | — | — | WO | disclosed |
| US-20020035110-A1 | Anti-obesity 1,2,3,4,10,10-a-hexahydropy razino [1,2-a] indoles | VERNALIS RESEARCH LIMITED, A BRITISH COMPANY (GB) | 2002-03-21 | — | — | US | disclosed |
| EP-1147110-A1 | PYRAZINO(AZA)INDOLE DERIVATIVES | VERNALIS RESEARCH LIMITED (GB) | 2001-10-24 | — | — | EP | disclosed |
| WO-2000044753-A1 | PIRAZINO(AZA)INDOLE DERIVATIVES | VERNALIS RESEARCH LIMITED (GB) | 2000-08-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040092525-A1 | Pirazino(aza)indole derivatives | PIR, GPR119, INMT | ALOX15 1379/4885KDM4E 1333/4885ALDH1A1 452/4885 |
| US-20050239789-A1 | Anti-obesity 1,2,3,4,10,10a-hexahydropyrazino[1,2-a] indoles | GPR119, INSR, GIPR | ALOX15 846/4885KDM4E 739/4885ALDH1A1 368/4885 |
| US-20030216401-A1 | Anti-obesity 1, 2, 3, 4, 10, 10a-hexahydropyrazino[1, 2-a] indoles | GPR119, INSR, IRS1 | ALOX15 184/4885KDM4E 1176/4885ALDH1A1 254/4885 |
| US-20070106076-A1 | Anti-obesity 1,2,3,4,10,10a-hexahydropyrazino [1,2-a] indoles | GPR119, INSR, GIPR | ALOX15 846/4885KDM4E 739/4885ALDH1A1 368/4885 |
| US-20020169163-A1 | Piperazine derivatives | GPR119, SLC5A2, DPP4 | ALOX15 1001/4885KDM4E 2045/4885ALDH1A1 1203/4885 |
| US-20020035110-A1 | Anti-obesity 1,2,3,4,10,10-a-hexahydropy razino [1,2-a] indoles | GPR119, HTR1D, HTR1A | ALOX15 261/4885KDM4E 657/4885ALDH1A1 225/4885 |
| US-20060160816-A1 | Pirazino(AZA) indole derivatives | PIR, GPR119, INMT | ALOX15 1347/4885KDM4E 1461/4885ALDH1A1 602/4885 |
| US-20040039200-A1 | Pirazino(AZA)indole derivatives | PIR, GPR119, INMT | ALOX15 1379/4885KDM4E 1333/4885ALDH1A1 452/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.